TransCode Therapeutics, Inc. a annoncé la publication de recherches précliniques soutenant l'application de son candidat ...

BOSTON - TransCode Therapeutics, Inc. (NASDAQ:RNAZ) a annoncé aujourd’hui que son principal candidat thérapeutique, TTX-MC138, a démontré son efficacité dans des modèles précliniques de glioblastome m ...

Transcode Therapeutics Inc : Transcode Therapeutics Inc : l'essai clinique de phase 2a de TTX-MC138 est attendu au premier ...

TransCode Therapeutics ( ($RNAZ) ) just unveiled an update. On January 6, 2026, TransCode Therapeutics announced the publication in the Journal of ...

Investing.com -- L’action de TransCode Therapeutics (NASDAQ:RNAZ) a bondi de 18% mardi après que la société a publié des données précliniques montrant que son candidat principal, TTX-MC138, a démontré ...

TransCode Therapeutics, Inc. (NASDAQ: RNAZ), a clinical stage company pioneering immuno-oncology and RNA therapeutics for the treatment of high risk and advanced cancer, today announced the ...

Investing.com -- TransCode Therapeutics (NASDAQ:RNAZ) stock surged 18% on Tuesday after the company published preclinical data showing its lead candidate TTX-MC138 demonstrated therapeutic potential ...

Publishes Preclinical Data Supporting TTX-MC138 For Glioblastoma. TransCode Therapeutics (NASDAQ: RNAZ) announced the publication of peer-reviewed preclinical research supporting the use of its lead ...

For two decades, the video streaming industry has operated under the dangerous assumption that computing ... Read More ...

Docker is an important tool for developers and for running apps across networks, and it has many uses for the pro and ...

Reviva Pharmaceuticals Holdings Inc. may be headed back to the clinic for another phase III study of brilaroxazine in treating schizophrenia. The U.S. FDA recommended the second study for the ...

Detailed price information for Transcode Therapeutics Inc (RNAZ-Q) from The Globe and Mail including charting and trades.